Benign Prostatic HyperplasiaNCT07357012
A Smart Wearable Device for Monitoring Urination Function in Benign Prostatic Hyperplasia
An observational study of Benign Prostatic Hyperplasia, run by Peking University Third Hospital at 2 sites in China.
Trial summary
Benign Prostatic Hyperplasia (BPH) is a common condition that can cause bothersome urination problems and reduce quality of life. Accurately measuring how the bladder empties is important for diagnosis and treatment, but current methods like uroflowmetry can be inconvenient and are done only at a clinic. Read more about this study
- Who is it for?
- Any age, men only
- Conditions the study is for
- Benign Prostatic Hyperplasia
- What is being tested?
- Electrical Impedance Tomography (EIT) Wearable Monitoring Device
- How many people
- 40 participants
- Where
- 2 sitesChina
- Study dates
- 1 Feb 2026to 1 Aug 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Men only
- No healthy volunteers
- Child, Adult, Older adult
Study population: Adult male patients diagnosed with BPH who are scheduled for urodynamic evaluation
Who may be able to join
- Patients with BPH who need urodynamic tests to further evaluate the underlying pathophysiology of LUTS prior to invasive treatment.
- Patients who understand and agree with the written informed consent, and voluntary to participate in the study.
Who cannot join
- Patients with catheter-dependent urinary retention. Patients who cannot void > 150ml. Patients with uncontrolled acute urinary tract infections. Patients who suffer from severe mental illness or other diseases that may affect judgment or cooperation during the study.
- Patients with implanted cardiac pacemaker or other electronic implants that may potentially be interfered by the EIT device.
- Patients with other conditions who are deemed unsuitable for participation by the investigator.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
China2 sites, 2 recruiting
- Recruiting
Peking University Third Hospital
Beijing, HaiDian, 100191
- Not yet recruiting
Peking University Third Hospital
Beijing
Lin Xiushi, +086 15600338549, 2511110553@bjmu.edu.cn
About this study
Official title: An Intelligent Wearable Device Based on Electrical Impedance Tomography for Dynamic and Accurate Monitoring of Voiding Function in Patients With Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH) is a common condition that can cause bothersome urination problems and reduce quality of life. Accurately measuring how the bladder empties is important for diagnosis and treatment, but current methods like uroflowmetry can be inconvenient and are done only at a clinic.
This study aims to test a new, non-invasive smart wearable device that uses Electrical Impedance Tomography (EIT) to monitor bladder function in patients with BPH. The device is worn on the lower abdomen. In this study, participants will use this EIT device while also undergoing the standard uroflowmetry test. The main goal is to see how well the measurements from the new device (like urine flow rate and volume) agree with those from the standard test.
The study hopes to show that this wearable device can accurately and comfortably track bladder function over time. If successful, it could lead to a new tool for doctors to better monitor patients with BPH, even potentially at home.
Read the detailed description
Background: Benign Prostatic Hyperplasia (BPH) is a prevalent cause of Lower Urinary Tract Symptoms (LUTS). Current objective assessment tools like uroflowmetry have limitations, including single-point measurement and the need for a clinical setting. Electrical Impedance Tomography (EIT) is a non-invasive, radiation-free imaging technique that shows promise for dynamic, real-time monitoring of internal organs. Preliminary work by our team has developed a wearable EIT system capable of 3D reconstruction.
Objectives: The primary objective is to evaluate the accuracy and agreement of the EIT wearable device in determining key uroflowmetry parameters (maximum flow rate, average flow rate, voided volume) against traditional uroflowmetry as the reference standard. Secondary objectives include assessing its capability for dynamic bladder volume monitoring and exploring an AI-based analysis framework.
Study Design: This is a single-center, self-controlled, diagnostic consistency trial.
Inclusion criteria:
- Patients with BPH who need urodynamic tests to further evaluate the underlying pathophysiology of LUTS prior to invasive treatment.
- Patients who understand and agree with the written informed consent, and voluntary to participate in the study. .
Key exclusion criteria:
- Patients with catheter-dependent urinary retention.
- Patients who cannot void > 150ml.
- Patients with uncontrolled acute urinary tract infections.
- Patients who suffer from severe mental illness or other diseases that may affect judgment or cooperation during the study.
- Patients with implanted cardiac pacemaker or other electronic implants that may potentially be interfered by the EIT device.
- Patients with other conditions who are deemed unsuitable for participation by the investigator.
Interventions: Eligible participants will wear the EIT electrode array on the lower abdomen. After baseline emptying and controlled water ingestion, the EIT device will continuously monitor the filling phase until a strong urge to void. Participants will then void into a standard uroflowmeter, with the EIT device simultaneously recording the voiding process.
Primary Outcome: The agreement between EIT-reconstructed and uroflowmetry data during voiding, measured by temporal alignment error for key parameters and overall curve similarity.
Secondary Outcomes: Agreement under different bladder volumes, and subject acceptance via a comfort questionnaire.
Statistical Methods: Statistical analyses will be performed using R software version 4.5.1. Measurement data following a normal or approximately normal distribution will be expressed as mean ± standard deviation (x±s), and intergroup comparisons will use appropriate parametric tests (e.g., paired t-test for within-subject comparisons); data not meeting normality assumptions will be expressed as median (interquartile range) and analyzed using non-parametric tests (e.g., Wilcoxon signed-rank test). Agreement for continuous parameters (e.g., Qmax, VV) will be assessed using Bland-Altman plots with 95% limits of agreement and Intraclass Correlation Coefficient (ICC). Curve similarity will be assessed using methods such as Dynamic Time Warping (DTW) distance and Pearson correlation. A P-value < 0.05 will be considered statistically significant.
- Conditions
- Benign Prostatic Hyperplasia
- Being tested
- Electrical Impedance Tomography (EIT) Wearable Monitoring Device
- Medical subject headings
- Prostatic Hyperplasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electrical Impedance Tomography (EIT) Wearable Monitoring DeviceDiagnostic test
A non-invasive, portable device that uses an array of surface electrodes placed on the lower abdomen to measure bioimpedance changes. It reconstructs real-time, three-dimensional images and volume data of the bladder during filling and voiding phases.
| Study group | Role | What they receive |
|---|---|---|
| Benign Prostatic Hyperplasia (BPH) Patients | Not described Receives: Diagnostic Test: Electrical Impedance Tomography (EIT) Wearable Monitoring Device |
What is being measured
The primary outcome is the main question the study is designed to answer.
Agreement of Voiding Parameters Between EIT Device and Uroflowmetry
Measured: From device placement until completion of the voiding test, assessed on the day of the single study visit.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jan 2026
- Study start1 Feb 2026
- Primary completion1 Feb 2026
- Study completion1 Aug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Benign Prostatic HyperplasiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Liu Zhuo, Principal investigator, Peking University Third Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07357012
- Sponsor's protocol ID
- M20251231
- Status last verified
- Jun 2026
- First submitted
- 12 Jan 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Liu Z, Lin X, Zhuo L, Li Q, Chen J, Zhu Z, Li X, Xiao C, Zhang S, Sun J, Liu K. An intelligent wearable device based on electrical impedance tomography for dynamic and accurate monitoring of voiding function in patients with benign prostatic hyperplasia: protocol for a single-centre self-controlled diagnostic consistency study. Transl Androl Urol. 2026 May 30;15(5):181. doi: 10.21037/tau-2026-1-0156. Epub 2026 May 26.
PubMed 42293860
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Intelligent Wearable Device Based on Electrical Impedance Tomography for Dynamic and Accurate Monitoring of Voiding Function in Patients With Benign Prostatic Hyperplasia
- ClinicalTrials.gov ID
- NCT07357012
- Acronym / sponsor ID
- M20251231
- Conditions
- Benign Prostatic Hyperplasia
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 1 Feb 2026 (actual)
- Study completion
- 1 Aug 2027 (estimated)
- First posted
- 21 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Benign Prostatic Hyperplasia (BPH) is a common condition that can cause bothersome urination problems and reduce quality of life. Accurately measuring how the bladder empties is important for diagnosis and treatment, but current methods like uroflowmetry can be inconvenient and are done only at a clinic.
This study aims to test a new, non-invasive smart wearable device that uses Electrical Impedance Tomography (EIT) to monitor bladder function in patients with BPH. The device is worn on the lower abdomen. In this study, participants will use this EIT device while also undergoing the standard uroflowmetry test. The main goal is to see how well the measurements from the new device (like urine flow rate and volume) agree with those from the standard test.
The study hopes to show that this wearable device can accurately and comfortably track bladder function over time. If successful, it could lead to a new tool for doctors to better monitor patients with BPH, even potentially at home.
Detailed description
Background: Benign Prostatic Hyperplasia (BPH) is a prevalent cause of Lower Urinary Tract Symptoms (LUTS). Current objective assessment tools like uroflowmetry have limitations, including single-point measurement and the need for a clinical setting. Electrical Impedance Tomography (EIT) is a non-invasive, radiation-free imaging technique that shows promise for dynamic, real-time monitoring of internal organs. Preliminary work by our team has developed a wearable EIT system capable of 3D reconstruction.
Objectives: The primary objective is to evaluate the accuracy and agreement of the EIT wearable device in determining key uroflowmetry parameters (maximum flow rate, average flow rate, voided volume) against traditional uroflowmetry as the reference standard. Secondary objectives include assessing its capability for dynamic bladder volume monitoring and exploring an AI-based analysis framework.
Study Design: This is a single-center, self-controlled, diagnostic consistency trial.
Inclusion criteria:
- Patients with BPH who need urodynamic tests to further evaluate the underlying pathophysiology of LUTS prior to invasive treatment.
- Patients who understand and agree with the written informed consent, and voluntary to participate in the study. .
Key exclusion criteria:
- Patients with catheter-dependent urinary retention.
- Patients who cannot void > 150ml.
- Patients with uncontrolled acute urinary tract infections.
- Patients who suffer from severe mental illness or other diseases that may affect judgment or cooperation during the study.
- Patients with implanted cardiac pacemaker or other electronic implants that may potentially be interfered by the EIT device.
- Patients with other conditions who are deemed unsuitable for participation by the investigator.
Interventions: Eligible participants will wear the EIT electrode array on the lower abdomen. After baseline emptying and controlled water ingestion, the EIT device will continuously monitor the filling phase until a strong urge to void. Participants will then void into a standard uroflowmeter, with the EIT device simultaneously recording the voiding process.
Primary Outcome: The agreement between EIT-reconstructed and uroflowmetry data during voiding, measured by temporal alignment error for key parameters and overall curve similarity.
Secondary Outcomes: Agreement under different bladder volumes, and subject acceptance via a comfort questionnaire.
Statistical Methods: Statistical analyses will be performed using R software version 4.5.1. Measurement data following a normal or approximately normal distribution will be expressed as mean ± standard deviation (x±s), and intergroup comparisons will use appropriate parametric tests (e.g., paired t-test for within-subject comparisons); data not meeting normality assumptions will be expressed as median (interquartile range) and analyzed using non-parametric tests (e.g., Wilcoxon signed-rank test). Agreement for continuous parameters (e.g., Qmax, VV) will be assessed using Bland-Altman plots with 95% limits of agreement and Intraclass Correlation Coefficient (ICC). Curve similarity will be assessed using methods such as Dynamic Time Warping (DTW) distance and Pearson correlation. A P-value < 0.05 will be considered statistically significant.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Benign Prostatic Hyperplasia (BPH) Patients | – | Diagnostic Test: Electrical Impedance Tomography (EIT) Wearable Monitoring Device |
Who may qualify
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Adult male patients diagnosed with BPH who are scheduled for urodynamic evaluation
Key inclusion criteria (2 listed)
- Patients with BPH who need urodynamic tests to further evaluate the underlying pathophysiology of LUTS prior to invasive treatment.
- Patients who understand and agree with the written informed consent, and voluntary to participate in the study.
Key exclusion criteria (3 listed)
- Patients with catheter-dependent urinary retention. Patients who cannot void > 150ml. Patients with uncontrolled acute urinary tract infections. Patients who suffer from severe mental illness or other diseases that may affect judgment or cooperation during the study.
- Patients with implanted cardiac pacemaker or other electronic implants that may potentially be interfered by the EIT device.
- Patients with other conditions who are deemed unsuitable for participation by the investigator.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electrical Impedance Tomography (EIT) Wearable Monitoring DeviceA non-invasive, portable device that uses an array of surface electrodes placed on the lower abdomen to measure bioimpedance changes. It reconstructs real-time, three-dimensional images and volume data of the bladder during filling and voiding phases. | Diagnostic test | Benign Prostatic Hyperplasia (BPH) Patients |
Primary outcome
Agreement of Voiding Parameters Between EIT Device and Uroflowmetry
Time frame: From device placement until completion of the voiding test, assessed on the day of the single study visit.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Derived from this study: PubMed 42293860Liu Z, Lin X, Zhuo L, Li Q, Chen J, Zhu Z, Li X, Xiao C, Zhang S, Sun J, Liu K. An intelligent wearable device based on electrical impedance tomography for dynamic and accurate monitoring of voiding function in patients with benign prostatic hyperplasia: protocol for a single-centre self-controlled diagnostic consistency study. Transl Androl Urol. 2026 May 30;15(5):181. doi: 10.21037/tau-2026-1-0156. Epub 2026 May 26.
- Individual participant dataSharing planned: No
Related trials for Benign Prostatic Hyperplasia
Not yet recruitingPhase 3
Efficacy and Safety of Two Fixed-dose Combinations in Men With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. (BENIPRO)
Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Not yet recruiting
Anterior Bridge-Preserving Versus Conventional Early Apical Release in Bipolar Enucleation of the Prostate
Benign Prostatic Hyperplasia, Benign Prostatic Obstruction
Not yet recruiting
Anterior Bridge-Preserving Versus Conventional Early Apical Release During Holmium Laser Enucleation of the Prostate
Benign Prostatic Hyperplasia, Benign Prostatic Obstruction
RecruitingObservational study
Perioperative Parameter and Treatment Outcomes of Surgical Treatment for Benign Prostate Hyperplasia in Hong Kong
Benign Prostatic Hyperplasia
Recruiting
Learning Curve of Tri-lobar HoLEP Versus En-bloc HoLEP
Benign Prostatic Hyperplasia With Outflow Obstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Liu Zhuo principal investigator
Peking University Third Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Benign Prostatic Hyperplasia, run by Peking University Third Hospital at 2 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lin Xiushi (+086 15600338549, 2511110553@bjmu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Agreement of Voiding Parameters Between EIT Device and Uroflowmetry (time frame: From device placement until completion of the voiding test, assessed on the day of the single study visit.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07357012, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.